Geode Capital Management LLC Buys 14,816 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID)

Geode Capital Management LLC grew its stake in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 1.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,317,330 shares of the company’s stock after buying an additional 14,816 shares during the quarter. Geode Capital Management LLC’s holdings in Ovid Therapeutics were worth $1,555,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Driehaus Capital Management LLC bought a new stake in Ovid Therapeutics during the 2nd quarter worth $1,077,000. GSA Capital Partners LLP boosted its stake in shares of Ovid Therapeutics by 118.0% during the third quarter. GSA Capital Partners LLP now owns 260,509 shares of the company’s stock valued at $307,000 after purchasing an additional 141,002 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Ovid Therapeutics by 4,128.7% during the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock worth $260,000 after purchasing an additional 215,189 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Ovid Therapeutics in the third quarter valued at approximately $102,000. Finally, Barclays PLC increased its stake in shares of Ovid Therapeutics by 311.2% in the third quarter. Barclays PLC now owns 84,175 shares of the company’s stock valued at $98,000 after buying an additional 63,702 shares during the period. 72.24% of the stock is currently owned by institutional investors and hedge funds.

Ovid Therapeutics Trading Down 5.5 %

NASDAQ OVID opened at $0.91 on Thursday. Ovid Therapeutics Inc. has a 12 month low of $0.68 and a 12 month high of $4.10. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $64.61 million, a PE ratio of -1.94 and a beta of 0.34. The business’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.06.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Tuesday, November 12th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.15 million. On average, analysts expect that Ovid Therapeutics Inc. will post -0.48 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Ovid Therapeutics in a report on Wednesday, December 4th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.04.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.